Friendly Fire After the Infusion

Clinical Vignette

A 62-year-old man with recurrent HPV-positive oropharyngeal squamous cell carcinoma presents to the emergency department with two weeks of progressive exertional dyspnea and a dry, nonproductive cough. His cancer was treated definitively with cisplatin and radiation two and a half years ago, but pulmonary metastases appeared six months ago and he began pembrolizumab monotherapy; he has now completed eight cycles with a partial response. His other history includes a 40 pack-year smoking history with moderate chronic obstructive pulmonary disease, hypertension, and dyslipidemia.

Over the past two weeks his exercise tolerance has fallen from walking a block to becoming breathless while dressing, and for the last four days he has had low-grade fevers to 38.1 C, fatigue, and a 4-kilogram weight loss. He denies purulent sputum, hemoptysis, pleuritic chest pain, orthopnea, leg swelling, sick contacts, or recent travel. Two days ago his oncologist started empiric ceftriaxone and azithromycin for suspected community-acquired pneumonia, but his dyspnea has worsened and he now requires supplemental oxygen.

On examination, temperature is 38.0 C, heart rate 98/min, blood pressure 132/72 mmHg, respiratory rate 24/min, and oxygen saturation 89% on room air, improving to 95% on 6 L/min nasal cannula. He is chronically ill-appearing but not in shock. Lung examination reveals diffuse fine bibasilar inspiratory crackles without wheezes, dullness, or signs of consolidation. There is no lower extremity edema, no jugular venous distension, no calf tenderness, and no oropharyngeal pooling or dental infection. Laboratory studies show white blood cell count 11.2 x 10^3/uL with a normal differential and no eosinophilia, absolute eosinophil count 0.1 x 10^3/uL, hemoglobin 12.1 g/dL, creatinine 0.9 mg/dL, D-dimer 1.1 ug/mL, C-reactive protein 112 mg/L, and procalcitonin 0.06 ng/mL. Respiratory viral polymerase chain reaction testing, including SARS-CoV-2, influenza, and RSV, is negative, blood cultures are drawn, and serum beta-D-glucan and galactomannan are not detected. An echocardiogram shows normal left ventricular function.

CT pulmonary angiography demonstrates no pulmonary embolism but reveals bilateral, lower-lobe-predominant ground-glass opacities with fine reticulation and peripheral perilobular accentuation, without consolidation, cavitation, pleural effusion, nodules, or mediastinal lymphadenopathy. Because he is worsening despite antibacterial therapy, bronchoscopy is performed; bronchoalveolar lavage is negative for bacteria, mycobacteria, fungi, and respiratory viruses, cytology is benign, and the lavage differential shows a lymphocytic predominance. The imaging is shown below.

Axial CT chest showing bilateral ground-glass opacities characteristic of checkpoint inhibitor pneumonitis

Axial CT of the chest: bilateral ground-glass opacities with fine reticulation — the classic radiographic pattern of checkpoint inhibitor pneumonitis.

Question 1

In this patient on pembrolizumab, what is the most likely diagnosis?

Select one option to submit your answer and view live poll results.


Question 2

Which statement best describes the diagnostic approach to this condition?

Select one option to submit your answer and view live poll results.


Question 3

After bronchoalveolar lavage returns negative, what is the most appropriate management of this patient's Grade 3 pneumonitis?

Select one option to submit your answer and view live poll results.


Answer the question above to reveal the rationale.
Answer the question above to reveal the rationale.

References

Naidoo J, Wang X, Woo KM, et al. Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. Journal of Clinical Oncology. 2017;35(7):709-717.

DOI: 10.1200/JCO.2016.68.2005

Schneider BJ, Naidoo J, Santomasso BD, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. Journal of Clinical Oncology. 2021;39(36):4073-4126.

DOI: 10.1200/JCO.21.01940

Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline. Journal of Clinical Oncology. 2018;36(17):1714-1768.

DOI: 10.1200/JCO.2017.77.6385

Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2017;28(suppl 4):iv119-iv142.

DOI: 10.1093/annonc/mdx225

Habib T, Abu-Abaa M, Kolman-Taddeo D. Nivolumab-Induced Organizing Pneumonia in Management of Non-small Cell Lung Carcinoma: A Case Report. Cureus. 2023;15(5):e39217. [CT figure source — CC BY 4.0.]

DOI: 10.7759/cureus.39217


Keep Exploring

Move between cases

Use the published-case sequence when you want to keep scrolling, or branch into related topics when a case opens up a new clinical thread.

Browse all cases

Newer case

You are at the newest published case.

You are at the newest published case in this sequence.

Case index

Jump back into the full library

Search by organism, syndrome, or concept when you want to branch out instead of staying in the newest-case sequence.

Open the case hub

Older case

Jul 7, 2026

The Right Lower Quadrant in the Wrong White Count

GI & DiarrhealOpportunistic Infection

A profoundly neutropenic patient on cisplatin-etoposide develops right lower quadrant pain and cecal wall thickening while on cefepime — testing whether the standard neutropenic fever regimen is enough for typhlitis.

Open case